ADMA Biologics, Inc. (NASDAQ:ADMA) Stake Raised by Amalgamated Bank

Amalgamated Bank raised its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 803.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 68,169 shares of the biotechnology company's stock after acquiring an additional 60,620 shares during the period. Amalgamated Bank's holdings in ADMA Biologics were worth $1,363,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its position in ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock valued at $69,454,000 after purchasing an additional 92,281 shares during the period. Seven Eight Capital LP acquired a new stake in shares of ADMA Biologics in the second quarter valued at about $1,992,000. Louisiana State Employees Retirement System purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at about $2,253,000. Point72 Asset Management L.P. acquired a new position in ADMA Biologics during the 2nd quarter worth approximately $1,157,000. Finally, New York State Teachers Retirement System purchased a new position in ADMA Biologics in the 3rd quarter worth approximately $1,821,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright boosted their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Finally, Raymond James lifted their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday, November 8th.

Insiders Place Their Bets

In other news, CEO Adam S. Grossman sold 236,889 shares of the company's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Adam S. Grossman sold 236,889 shares of the firm's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the business's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the transaction, the chief operating officer now owns 449,088 shares of the company's stock, valued at $7,589,587.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 466,900 shares of company stock valued at $8,224,121 over the last three months. Company insiders own 3.70% of the company's stock.

ADMA Biologics Stock Performance

Shares of NASDAQ:ADMA traded down $0.89 during trading on Thursday, reaching $20.58. 1,797,412 shares of the company's stock traded hands, compared to its average volume of 3,660,826. The stock has a market capitalization of $4.80 billion, a P/E ratio of 73.79 and a beta of 0.64. ADMA Biologics, Inc. has a 12 month low of $3.60 and a 12 month high of $23.64. The company has a 50 day moving average of $18.42 and a 200-day moving average of $14.22. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period in the previous year, the firm posted $0.01 earnings per share. On average, equities analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.